The U.S. Department of Justice is using the False Claims Act to pursue private equity investors for alleged violations committed by portfolio companies. While several case resolutions have become public, multiple ongoing cases remain confidential. This article describes recent FCA case settlements involving private equity and what proactive steps investors can take to protect themselves. Co-chair of the Healthcare Government Enforcement & False Claims Act Defense practice Kirk Ogrosky and Life Sciences and Healthcare partner Matt Wetzel of Goodwin explain more in this byline article. Read the Compliance Cosmos article here.